Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358721 · ClinicalTrials.gov registry record · Phase 1
Phase I Biomarker Study (BMS-936558)
A Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
- 14
- Study locations
NCT01358721: Completed Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
NCT01358721 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 119 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (51% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358721, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
Primary Outcome
The objective of the study was to investigate the pharmacodynamic immunomodulatory activity of anti-PD-1 antibody in activated and memory T cells with metastatic clear-cell Renal Cell Carcinoma (RCC)
Conditions Studied
Interventions
- DRUG BMS-936558 (Anti-PD-1)
Study Locations (14)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana Farber Cancer Inst - Boston
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Upmc Cancer Pavilion - Pittsburgh
Other
- Local Institution - Villejuif
- Local Institution - Pamplona
California
- Ucsf Helen Diller Family Comprehensive Cancer Center - San Francisco
Connecticut
- Yale University School Of Medicine - New Haven
Florida
- H. Lee Moffitt Cancer Center - Tampa
Illinois
- University Of Chicago Medical Center - Chicago
Maryland
- The Bunting-Blaustein Cancer Research Building - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2011-09-23 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
What the finished NCT01358721 record still lists
NCT01358721 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which BMS-936558 (Anti-PD-1) is the first listed.
NCT01358721 lists 14 locations in 11 states (Massachusetts, Pennsylvania, Other).
Frequently Asked Questions
What is clinical trial NCT01358721 about?
NCT01358721 is a clinical study titled "Phase I Biomarker Study (BMS-936558)". The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
What is the current status of trial NCT01358721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2011-09-23. Estimated completion is 2019-05-22.
What conditions does trial NCT01358721 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT01358721?
The interventions under investigation include: BMS-936558 (Anti-PD-1) (DRUG).
Who is sponsoring clinical trial NCT01358721?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358721 being conducted?
This trial has 14 study locations across California, Connecticut, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01358721's enrollment target sits among peer trials
119 47th of 121 higher than 75 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI